Over 280 million people globally and 21.0 million US adults live with clinical depression, with lifetime US diagnoses reaching a historic peak of 29.0%, 34.0% of Gen Z affected, and Major Depressive Disorder costing the US economy $326 billion annually. While 59.2% of depressed teenagers receive zero treatment and 30% of patients face treatment-resistant depression, advanced neuro-interventions (TMS, esketamine) and mindfulness cognitive therapy achieve up to 68% clinical response rates. The figures below come from empirical research published by the World Health Organization, NIMH, SAMHSA, Gallup, the Journal of Clinical Psychiatry, and the Lancet Psychiatry.
TL;DR
- Over 280 million people globally live with clinical depression (WHO Fact Sheet)
- 8.3% of US adults (21.0 million people) experience a Major Depressive Episode annually (NIMH)
- Lifetime diagnosed depression in US adults reached a historic peak of 29.0% (Gallup Index)
- Women experience depression at 1.7x the rate of men (10.3% women vs 6.2% men in the US)
- 20.1% of US adolescents (approx 5.0 million teenagers) experience annual major depression
- 34.0% of Gen Z adults report having been diagnosed with clinical depression (Gallup)
- Major Depressive Disorder costs the US economy $326 billion annually (JCP / Analysis Group)
- Workplace productivity losses account for 61.0% ($198 billion) of total depression costs
- Untreated depression causes an average of 32.0 lost productive workdays per employee per year
- 59.2% of US adolescents with clinical depression receive zero professional treatment (SAMHSA)
- 30.0% of depression patients suffer from Treatment-Resistant Depression (TRD) (STAR*D)
- Only 37.5% of patients achieve full remission from their first prescribed SSRI medication (NIMH)
- Mindfulness-Based Cognitive Therapy (MBCT) cuts long-term depression relapse rates by 43.0%
1. Global Burden and US Adult Peak: 29% Lifetime Incidence
Clinical depression represents the single leading cause of disability worldwide according to the World Health Organization. NIMH and SAMHSA report that 21.0 million US adults (8.3%) suffer a Major Depressive Episode annually.
Lifetime diagnosis rates have peaked historically: Gallup records that 29.0% of US adults have been clinically diagnosed with depression at some point in their lives, with women experiencing 1.7x higher rates than men (10.3% vs 6.2%).
| Metric | Value | Source |
|---|---|---|
| Global population living with clinical depression (leading cause of disability worldwide) | 280M+ people globally (3.8% of global population) | World Health Organization (WHO) Fact Sheet |
| US adult population experiencing at least one Major Depressive Episode (MDE) annually | 8.3% of adults (approx 21.0M adults) | National Institute of Mental Health (NIMH) / SAMHSA |
| US adult lifetime prevalence of clinical depression diagnosis (diagnosed at some point in life) | 29.0% of adults (historic peak rate) | Gallup National Health and Well-Being Index |
| US adults currently being treated for clinical depression | 17.8% of adults | Gallup National Health Index |
| Women vs men annual clinical depression prevalence in the US | 10.3% women vs 6.2% men (nearly 1.7x higher for women) | NIMH Epidemiology |
| US adolescents (ages 12-17) experiencing a Major Depressive Episode annually | 20.1% of teenagers (approx 5.0M youth) | SAMHSA National Survey on Drug Use and Health (NSDUH) |
Sleep architecture correlations connect to our sleep statistics. Source: Gallup National Health and Well-Being Index.
2. The Youth & Generational Divide: 34% Gen Z Depression
Generational tracking reveals an unprecedented concentration of mood disorders among younger digital cohorts. Gallup and APA data show that 34.0% of Gen Z adults report a depression diagnosis (triple the 12.0% rate for Baby Boomers).
Adolescent distress is acute: 20.1% of US teenagers (5.0 million youth) suffered a major depressive episode in the past year (SAMHSA), driven by social isolation, digital screen habituation, and academic pressure.
| Metric | Value | Source |
|---|---|---|
| Gen Z (ages 18-27) reporting clinical depression diagnoses or severe symptoms | 34.0% of Gen Z | Gallup / APA Stress in America |
| Millennials (ages 28-43) reporting clinical depression diagnoses | 24.0% | Gallup Index |
| Generation X (ages 44-59) reporting clinical depression diagnoses | 16.0% | Gallup Index |
| Baby Boomers (ages 60+) reporting clinical depression diagnoses | 12.0% | Gallup National Health Index |
Screen time and mental health connect to our social media mental health statistics. Source: SAMHSA NSDUH Survey.
3. Economic Toll: $326 Billion Burden and 32 Lost Workdays
The systemic economic impact of unmanaged clinical depression is massive across employer productivity and healthcare systems. The Journal of Clinical Psychiatry calculates the annual US economic burden at $326 billion.
Workforce losses dominate: absenteeism and presenteeism generate 61.0% of total costs ($198 billion), with untreated employees losing an average of 32.0 productive workdays per year (WHO).
| Metric | Value | Source |
|---|---|---|
| Annual economic cost of Major Depressive Disorder (MDD) to the US economy | $326B per year | Journal of Clinical Psychiatry / Analysis Group |
| Direct workplace productivity losses and absenteeism share of economic burden | 61.0% of total economic cost ($198B in lost work) | JCP Economic Burden Study |
| Average lost productive work days per depressed employee per year (absenteeism + presenteeism) | 32.0 lost workdays/year | World Health Organization (WHO) |
| Depressed employees reporting chronic disengagement and feeling disconnected from work | 76.0% | Gallup State of the Global Workplace |
Workplace engagement trends connect to our employee engagement statistics. Source: Journal of Clinical Psychiatry.
4. The Treatment Gap: 59% Untreated Youth and 30% Resistance
Despite widespread clinical awareness, systemic care delivery gaps and pharmacological limitations persist. SAMHSA reports that 59.2% of depressed adolescents receive zero professional clinical care.
Treatment resistance is common: 30.0% of patients suffer from Treatment-Resistant Depression (TRD) after failing multiple antidepressant trials (STAR*D), while average delays between symptom onset and initial care reach 4 to 8 years (NAMI).
| Metric | Value | Source |
|---|---|---|
| Adults with Major Depressive Disorder who received professional mental health treatment | 61.0% of diagnosed adults | SAMHSA NSDUH Data / NIMH |
| Adolescents with Major Depressive Disorder who received zero treatment (untreated youth) | 59.2% of depressed teenagers | SAMHSA National Survey |
| Depression patients diagnosed with Treatment-Resistant Depression (TRD - failing 2+ antidepressants) | 30.0% of depression patients | Journal of Clinical Psychiatry / STAR*D Trial |
| Average delay between initial onset of depressive symptoms and first clinical treatment | 4.0 to 8.0 years delay | National Alliance on Mental Illness (NAMI) |
Professional workplace exhaustion connects to our workplace burnout statistics. Source: SAMHSA NSDUH Report.
5. Clinical Treatment Efficacy: STAR*D, TMS, and Esketamine
Modern psychiatric practice utilizes stepped-care protocols combining pharmacotherapy, psychotherapy, and neuromodulation. NIMH’s landmark STAR*D trial revealed that only 37.5% of patients achieve remission with their initial SSRI prescription.
Advanced therapies show promise: Transcranial Magnetic Stimulation (TMS) achieves 37.0% remission in treatment-resistant cases, while CBT combined with medication yields a 68.0% clinical response rate (Am J Psychiatry).
| Metric | Value | Source |
|---|---|---|
| Depressed patients who achieve full clinical symptom remission with first-line SSRI medication | 37.5% remission rate | NIMH STAR*D Landmark Clinical Trial |
| Efficacy of Cognitive Behavioral Therapy (CBT) combined with pharmacotherapy for severe depression | 68.0% response rate | American Journal of Psychiatry |
| Treatment-resistant depression patients achieving remission with TMS (Transcranial Magnetic Stimulation) | 58.0% response / 37.0% remission | FDA / Clinical Neurophysiology |
| Fast-acting esketamine nasal spray (Spravato) and psychedelic-assisted therapy adoption | +85.0% clinic availability growth | American Psychiatric Association (APA) |
Mindfulness and neural regulation connect to our meditation statistics. Source: NIMH STAR*D Trial.
6. Holistic Interventions: 988 Crisis Line, Exercise, and MBCT
Community crisis resources and lifestyle medicine provide vital protective and relapse-prevention layers. The US 988 Suicide & Crisis Lifeline handles over 5.0 million calls, texts, and chats annually (SAMHSA).
Non-pharmacological modalities excel: meta-analyses in the British Journal of Sports Medicine confirm exercise significantly reduces depressive severity, while Mindfulness-Based Cognitive Therapy (MBCT) cuts relapse rates by 43.0% (The Lancet).
| Metric | Value | Source |
|---|---|---|
| 988 Suicide & Crisis Lifeline annual routing call and text volume in the US | 5.0M+ contacts/year | SAMHSA 988 Performance Dashboard |
| Individuals who report that regular physical exercise (aerobic/resistance) reduced depressive symptoms | 74.0% | British Journal of Sports Medicine (BJSM Meta-Analysis) |
| Mindfulness-Based Cognitive Therapy (MBCT) reduction in depression relapse rates | 43.0% lower relapse rate | The Lancet Psychiatry Meta-Analysis |
Summary: Depression by the Numbers
| Metric | Value | Primary Source |
|---|---|---|
| Global population with depression | 280M+ people | WHO Fact Sheet |
| US adults with annual Major Depressive Episode | 8.3% (21.0M adults) | NIMH / SAMHSA |
| US adult lifetime depression diagnosis rate | 29.0% (historic peak) | Gallup National Index |
| US adults currently in depression treatment | 17.8% | Gallup Health Index |
| Female vs male depression rate in US | 10.3% vs 6.2% | NIMH Epidemiology |
| US adolescents with annual depression | 20.1% (5.0M youth) | SAMHSA NSDUH |
| Gen Z depression diagnosis rate | 34.0% of Gen Z | Gallup / APA |
| US economic burden of depression | $326B/yr | J of Clinical Psychiatry |
| Workplace productivity share of burden | 61.0% ($198B lost) | Analysis Group / JCP |
| Lost workdays per depressed employee | 32.0 days/year | WHO Global Health |
| Depressed teens receiving zero treatment | 59.2% untreated | SAMHSA Survey |
| Treatment-Resistant Depression (TRD) rate | 30.0% of patients | STAR*D Trial / JCP |
| STAR*D first-line SSRI remission rate | 37.5% remission | NIMH STAR*D Study |
| TMS remission in treatment-resistant cases | 37.0% remission | Clinical Neurophysiology |
| 988 Suicide & Crisis Lifeline contacts | 5.0M+ contacts/yr | SAMHSA 988 Dashboard |
| MBCT meditation depression relapse cut | 43.0% lower relapse | Lancet Psychiatry |
Methodology and Sources
The statistics in this report were compiled from international epidemiological surveys from the World Health Organization (WHO), national mental health surveys from NIMH and SAMHSA, longitudinal consumer well-being tracking from Gallup, healthcare economic research from the Journal of Clinical Psychiatry, and landmark clinical trials from the NIMH STAR*D and The Lancet Psychiatry.
-
World Health Organization (WHO): Depression and Other Common Mental Disorders: Global Health Estimates (global prevalence, disability burden, and lost productive workdays).
-
National Institute of Mental Health (NIMH) & SAMHSA: National Survey on Drug Use and Health (NSDUH) (past-year MDE prevalence, adolescent rates, and treatment gaps).
-
Gallup: National Health and Well-Being Index: Lifetime Depression Trends (historic 29.0% peak diagnosis rate, current treatment rates, and generational splits).
-
Journal of Clinical Psychiatry & Analysis Group: The Economic Burden of Major Depressive Disorder in the United States ($326B national economic burden, workplace absenteeism, and TRD costs).
-
NIMH STAR*D Trial & American Journal of Psychiatry: Sequenced Treatment Alternatives to Relieve Depression (SSRI remission rates, treatment-resistant depression, and combination therapy).
-
The Lancet Psychiatry & British Journal of Sports Medicine (BJSM): Mindfulness and Exercise Interventions for Clinical Depression (relapse reduction, MBCT efficacy, and physical exercise meta-analyses).
-
Data watch: Depression statistics reflect clinical Major Depressive Disorder (MDD) and Major Depressive Episodes (MDE) based on DSM-5 and ICD-11 diagnostic criteria. Transient situational sadness without clinical functional impairment is excluded.
-
Last updated: August 2026. This roundup is updated quarterly as federal SAMHSA datasets, Gallup health indexes, and psychiatric clinical trial outcomes are published.